首頁 > 市場調查報告書 > 製藥

疼痛

市場調查報告書

商品編碼

1726254

全球偏頭痛藥物市場：市場規模、佔有率、趨勢分析（按藥物、藥物類別、給藥途徑、年齡層、獲取方式和地區）、細分市場預測（2025-2030 年）

Migraine Drugs Market Size, Share & Trends Analysis Report By Treatment (Acute, Preventive), By Therapeutic Class, By Route Of Administration, By Age Group (Pediatric, Adult, Geriatric), By Availability, By Region, And Segment Forecasts, 2025 - 2030

出版日期: 2025年04月16日 | 出版商:

Grand View Research | 英文 159 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

偏頭痛藥物市場的成長與趨勢：

根據 Grand View Research, Inc. 的新報告，全球偏頭痛藥物市場預計到 2030 年將達到 133.4 億美元，2025 年至 2030 年的複合年成長率為 10.9%。這個市場的主要促進因素是疾病盛行率上升、新治療方法的開發、生活方式的改變和荷爾蒙藥物等因素。

偏頭痛是一種使人衰弱的神經系統疾病，其特徵是反覆發作劇烈的搏動性頭痛，持續三天或更長時間。偏頭痛會隨著運動而加劇，並妨礙患者進行正常的日常活動。約三分之一的發作會影響頭部、臉部和頸部的兩側。

在過去五年中，全球偏頭痛藥物市場相對停滯，主要由非專利曲坦類藥物和其他仿單標示外用藥主導。目前大多數處方藥，無論是急性治療或預防性治療，療效都較低且副作用較大。

安進/諾華的 CGRP mAb Aimovig 和梯瓦製藥的 Ajovy 的推出是改變偏頭痛預防治療模式的舉措。對於可能在 2019 年進入市場的藥品製造商（如禮來公司、Alder BioPharma 和 Biohaven Pharma）而言，定價可能是一個關鍵的區別因素，因為基於 CGRP 的療法都具有相似的功效和安全性。

偏頭痛藥物市場：概述

根據治療藥物，預防部分在 2024 年佔據市場最大收入佔有率，為 62.03%。急性部分在 2024 年佔據第二大市場收益佔有率。
按治療層級，CGRP 單株抗體領域在 2024 年佔據市場最大收入佔有率，為 56.68%。 CAGR 預計小分子拮抗劑診斷領域在預測期內將以最快的複合年成長率成長。
根據給藥途徑，注射劑在 2024 年佔據市場主導地位，銷售佔有率最大，為 69.48%。預計口服藥物部分在預測期內將呈現顯著的複合年成長率。
根據年齡層，成人群體將在 2024 年佔據市場最大收益佔有率，達到 52.92%，預計在預測期內將以顯著的複合年成長率成長。預計在預測期內，老年人群的複合年成長率將顯著成長。
根據收購模式，處方藥部門將在 2024 年佔據市場最大收益佔有率，達到 62.38%，預計在預測期內將以顯著的複合年成長率成長。

區域儀表板
市場規模、預測趨勢分析，2018 年至 2030 年：
北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 挪威
- 瑞典
- 丹麥
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 泰國
拉丁美洲
- 巴西
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 科威特

第10章競爭格局

主要市場參與企業的近期趨勢和影響分析
公司/競爭對手分類
供應商格局
- 主要經銷商和通路合作夥伴名單
- Key customers
- Key company market share analysis, 2023
- AbbVie Inc.
- Amgen Inc.
- Teva Pharmaceutical Industries Ltd.
- GSK plc
- Eli Lilly and Company
- Pfizer Inc.
- Bausch Health Companies Inc.
- Gensco Pharma
- Impel Pharmaceuticals Inc.
- Currax Pharmaceuticals LLC.
- Lundbeck

簡介目錄圖表

Product Code: GVR-2-68038-559-5

Migraine Drugs Market Growth & Trends:

The global migraine drugs market size is expected to reach USD 13.34 billion by 2030, registering a CAGR of 10.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is largely driven by factors such as a rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.

Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.

Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.

Launch of Amgen/ Novartis' CGRP mAb Aimovig and Teva Pharma's Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.

Migraine Drugs Market Report Highlights:

Based on treatment, the preventive segment led the market with the largest revenue share of 62.03% in 2024. The Acute segment held the second largest market revenue share in 2024.
Based on the therapeutic class, the CGRP monoclonal antibodies segment led the market with the largest revenue share of 56.68% in 2024. The CGRP small molecule antagonist diagnostics segment is anticipated to grow at the fastest CAGR over the forecast period.
Based on the route of administration, the injectable segment led the market with the largest revenue share of 69.48% in 2024. The oral segment is projected to witness a significant CAGR over the forecast period.
Based on age group, the adult segment led the market with the largest revenue share of 52.92% in 2024 and is anticipated to grow at a significant CAGR over the forecast period. The geriatric segment is anticipated to grow at a significant CAGR over the forecast period.
Based on availability, the prescription drugs segment led the market with the largest revenue share of 62.38% in 2024 and is anticipated to grow at a significant CAGR over the forecast period.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Treatment
- 1.2.2. Therapeutic Class
- 1.2.3. Route of Administration
- 1.2.4. Age Group
- 1.2.5. Availability
- 1.2.6. Regional scope
- 1.2.7. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
  - 1.4.5.1. Data for primary interviews in North America
  - 1.4.5.2. Data for primary interviews in Europe
  - 1.4.5.3. Data for primary interviews in Asia Pacific
  - 1.4.5.4. Data for primary interviews in Latin America
  - 1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Treatment and Therapeutic Class outlook
- 2.2.2. Route of Administration outlook
- 2.2.3. Age Group and Availability outlook
- 2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Migraine Drugs Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Increasing prevalence of migraines
  - 3.2.1.2. Advancements in drug development
  - 3.2.1.3. Growing awareness and diagnosis
- 3.2.2. Market restraint analysis
  - 3.2.2.1. High cost of development
  - 3.2.2.2. Regulatory challenges for new drug approvals
3.3. Migraine Drugs Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape
3.4. Pricing Analysis
3.5. Pipeline Analysis, by Phase

Chapter 4. Migraine Drugs Market: Treatment Estimates & Trend Analysis

4.1. Global Migraine Drugs Market: Treatment Dashboard
4.2. Global Migraine Drugs Market: Treatment Movement Analysis
4.3. Global Migraine Drugs Market by Treatment, Revenue
4.4. Acute
- 4.4.1. Acute market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Preventive
- 4.5.1. Preventive market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Migraine Drugs Market: Therapeutic Class Estimates & Trend Analysis

5.1. Global Migraine Drugs Market: Therapeutic Class Dashboard
5.2. Global Migraine Drugs Market: Therapeutic Class Movement Analysis
5.3. Global Migraine Drugs Market by Therapeutic Class, Revenue
5.4. CGRP monoclonal antibodies
- 5.4.1. CGRP monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. CGRP small molecule antagonists
- 5.5.1. CGRP small molecule antagonists market estimates and forecasts, 2018 to 2030 (USD Million)
5.6. Acetylcholine inhibitors/ neurotoxins
- 5.6.1. Acetylcholine inhibitors/ neurotoxins market estimates and forecasts, 2018 to 2030 (USD Million)
5.7. Triptans
- 5.7.1. Triptans market estimates and forecasts, 2018 to 2030 (USD Million)
5.8. Ditans
- 5.8.1. Ditans market estimates and forecasts, 2018 to 2030 (USD Million)
5.9. Ergot alkaloids
- 5.9.1. Ergot alkaloids market estimates and forecasts, 2018 to 2030 (USD Million)
5.10. NSAIDs
- 5.10.1. NSAIDs market estimates and forecasts, 2018 to 2030 (USD Million)
5.11. Others
- 5.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Migraine Drugs Market: Route of Administration Estimates & Trend Analysis

6.1. Global Migraine Drugs Market: Route of Administration Dashboard
6.2. Global Migraine Drugs Market: Route of Administration Movement Analysis
6.3. Global Migraine Drugs Market by Route of Administration, Revenue
6.4. Oral
- 6.4.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Injectable
- 6.5.1. Injectable market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Others
- 6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Migraine Drugs Market: Age Group Estimates & Trend Analysis

7.1. Global Migraine Drugs Market: Age Group Dashboard
7.2. Global Migraine Drugs Market: Age Group Movement Analysis
7.3. Global Migraine Drugs Market by Age Group, Revenue
7.4. Pediatric
- 7.4.1. Pediatric market estimates and forecasts, 2018 to 2030 (USD Million)
7.5. Adult
- 7.5.1. Adult market estimates and forecasts, 2018 to 2030 (USD Million)
7.6. Geriatric
- 7.6.1. Geriatric market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Migraine Drugs Market: Availability Estimates & Trend Analysis

8.1. Global Migraine Drugs Market: Availability Dashboard
8.2. Global Migraine Drugs Market: Availability Movement Analysis
8.3. Global Migraine Drugs Market by Availability, Revenue
8.4. Prescription Drugs
- 8.4.1. Prescription Drugs market estimates and forecasts, 2018 to 2030 (USD Million)
8.5. Over-the-Counter (OTC) Drugs
- 8.5.1. Over-the-Counter (OTC) Drugs market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Migraine Drugs Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration

9.1. Regional Dashboard
9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
9.3. North America
- 9.3.1. U.S.
  - 9.3.1.1. Key country dynamics
  - 9.3.1.2. Regulatory framework/ reimbursement structure
  - 9.3.1.3. Competitive scenario
  - 9.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.3.2. Canada
  - 9.3.2.1. Key country dynamics
  - 9.3.2.2. Regulatory framework/ reimbursement structure
  - 9.3.2.3. Competitive scenario
  - 9.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.3.3. Mexico
  - 9.3.3.1. Key country dynamics
  - 9.3.3.2. Regulatory framework/ reimbursement structure
  - 9.3.3.3. Competitive scenario
  - 9.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
9.4. Europe
- 9.4.1. UK
  - 9.4.1.1. Key country dynamics
  - 9.4.1.2. Regulatory framework/ reimbursement structure
  - 9.4.1.3. Competitive scenario
  - 9.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4.2. Germany
  - 9.4.2.1. Key country dynamics
  - 9.4.2.2. Regulatory framework/ reimbursement structure
  - 9.4.2.3. Competitive scenario
  - 9.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4.3. France
  - 9.4.3.1. Key country dynamics
  - 9.4.3.2. Regulatory framework/ reimbursement structure
  - 9.4.3.3. Competitive scenario
  - 9.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4.4. Italy
  - 9.4.4.1. Key country dynamics
  - 9.4.4.2. Regulatory framework/ reimbursement structure
  - 9.4.4.3. Competitive scenario
  - 9.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4.5. Spain
  - 9.4.5.1. Key country dynamics
  - 9.4.5.2. Regulatory framework/ reimbursement structure
  - 9.4.5.3. Competitive scenario
  - 9.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4.6. Norway
  - 9.4.6.1. Key country dynamics
  - 9.4.6.2. Regulatory framework/ reimbursement structure
  - 9.4.6.3. Competitive scenario
  - 9.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4.7. Sweden
  - 9.4.7.1. Key country dynamics
  - 9.4.7.2. Regulatory framework/ reimbursement structure
  - 9.4.7.3. Competitive scenario
  - 9.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.4.8. Denmark
  - 9.4.8.1. Key country dynamics
  - 9.4.8.2. Regulatory framework/ reimbursement structure
  - 9.4.8.3. Competitive scenario
  - 9.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
9.5. Asia Pacific
- 9.5.1. Japan
  - 9.5.1.1. Key country dynamics
  - 9.5.1.2. Regulatory framework/ reimbursement structure
  - 9.5.1.3. Competitive scenario
  - 9.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.5.2. China
  - 9.5.2.1. Key country dynamics
  - 9.5.2.2. Regulatory framework/ reimbursement structure
  - 9.5.2.3. Competitive scenario
  - 9.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.5.3. India
  - 9.5.3.1. Key country dynamics
  - 9.5.3.2. Regulatory framework/ reimbursement structure
  - 9.5.3.3. Competitive scenario
  - 9.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.5.4. Australia
  - 9.5.4.1. Key country dynamics
  - 9.5.4.2. Regulatory framework/ reimbursement structure
  - 9.5.4.3. Competitive scenario
  - 9.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.5.5. South Korea
  - 9.5.5.1. Key country dynamics
  - 9.5.5.2. Regulatory framework/ reimbursement structure
  - 9.5.5.3. Competitive scenario
  - 9.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.5.6. Thailand
  - 9.5.6.1. Key country dynamics
  - 9.5.6.2. Regulatory framework/ reimbursement structure
  - 9.5.6.3. Competitive scenario
  - 9.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
9.6. Latin America
- 9.6.1. Brazil
  - 9.6.1.1. Key country dynamics
  - 9.6.1.2. Regulatory framework/ reimbursement structure
  - 9.6.1.3. Competitive scenario
  - 9.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.6.2. Argentina
  - 9.6.2.1. Key country dynamics
  - 9.6.2.2. Regulatory framework/ reimbursement structure
  - 9.6.2.3. Competitive scenario
  - 9.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
9.7. Middle East & Africa
- 9.7.1. South Africa
  - 9.7.1.1. Key country dynamics
  - 9.7.1.2. Regulatory framework/ reimbursement structure
  - 9.7.1.3. Competitive scenario
  - 9.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.7.2. Saudi Arabia
  - 9.7.2.1. Key country dynamics
  - 9.7.2.2. Regulatory framework/ reimbursement structure
  - 9.7.2.3. Competitive scenario
  - 9.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.7.3. UAE
  - 9.7.3.1. Key country dynamics
  - 9.7.3.2. Regulatory framework/ reimbursement structure
  - 9.7.3.3. Competitive scenario
  - 9.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
- 9.7.4. Kuwait
  - 9.7.4.1. Key country dynamics
  - 9.7.4.2. Regulatory framework/ reimbursement structure
  - 9.7.4.3. Competitive scenario
  - 9.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

10.1. Recent Developments & Impact Analysis, By Key Market Participants
10.2. Company/Competition Categorization
10.3. Vendor Landscape
- 10.3.1. List of key distributors and channel partners
- 10.3.2. Key customers
- 10.3.3. Key company market share analysis, 2023
- 10.3.4. AbbVie Inc.
  - 10.3.4.1. Company overview
  - 10.3.4.2. Financial performance
  - 10.3.4.3. Product benchmarking
  - 10.3.4.4. Strategic initiatives
- 10.3.5. Amgen Inc.
  - 10.3.5.1. Company overview
  - 10.3.5.2. Financial performance
  - 10.3.5.3. Product benchmarking
  - 10.3.5.4. Strategic initiatives
- 10.3.6. Teva Pharmaceutical Industries Ltd.
  - 10.3.6.1. Company overview
  - 10.3.6.2. Financial performance
  - 10.3.6.3. Product benchmarking
  - 10.3.6.4. Strategic initiatives
- 10.3.7. GSK plc
  - 10.3.7.1. Company overview
  - 10.3.7.2. Financial performance
  - 10.3.7.3. Product benchmarking
  - 10.3.7.4. Strategic initiatives
- 10.3.8. Eli Lilly and Company
  - 10.3.8.1. Company overview
  - 10.3.8.2. Financial performance
  - 10.3.8.3. Product benchmarking
  - 10.3.8.4. Strategic initiatives
- 10.3.9. Pfizer Inc.
  - 10.3.9.1. Company overview
  - 10.3.9.2. Financial performance
  - 10.3.9.3. Product benchmarking
  - 10.3.9.4. Strategic initiatives
- 10.3.10. Bausch Health Companies Inc.
  - 10.3.10.1. Company overview
  - 10.3.10.2. Financial performance
  - 10.3.10.3. Product benchmarking
  - 10.3.10.4. Strategic initiatives
- 10.3.11. Gensco Pharma
  - 10.3.11.1. Company overview
  - 10.3.11.2. Financial performance
  - 10.3.11.3. Product benchmarking
  - 10.3.11.4. Strategic initiatives
- 10.3.12. Impel Pharmaceuticals Inc.
  - 10.3.12.1. Company overview
  - 10.3.12.2. Financial performance
  - 10.3.12.3. Product benchmarking
  - 10.3.12.4. Strategic initiatives
- 10.3.13. Currax Pharmaceuticals LLC.
  - 10.3.13.1. Company overview
  - 10.3.13.2. Financial performance
  - 10.3.13.3. Product benchmarking
  - 10.3.13.4. Strategic initiatives
- 10.3.14. Lundbeck
  - 10.3.14.1. Company overview
  - 10.3.14.2. Financial performance
  - 10.3.14.3. Product benchmarking
  - 10.3.14.4. Strategic initiatives

簡介目錄圖表

List of Tables

Table 1. List of abbreviation
Table 2. North America Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
Table 3. North America Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 4. North America Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 5. North America Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 6. North America Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 7. North America Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 8. U.S. Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 9. U.S. Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 10. U.S. Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 11. U.S. Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 12. U.S. Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 13. Canada Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 14. Canada Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 15. Canada Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 16. Canada Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 17. Canada Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 18. Europe Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
Table 19. Europe Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 20. Europe Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 21. Europe Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 22. Europe Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 23. Europe Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 24. Germany Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 25. Germany Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 26. Germany Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 27. Germany Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 28. Germany Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 29. UK Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 30. UK Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 31. UK Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 32. UK Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 33. UK Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 34. France Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 35. France Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 36. France Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 37. France Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 38. France Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 39. Italy Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 40. Italy Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 41. Italy Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 42. Italy Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 43. Italy Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 44. Spain Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 45. Spain Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 46. Spain Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 47. Spain Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 48. Spain Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 49. Denmark Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 50. Denmark Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 51. Denmark Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 52. Denmark Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 53. Denmark Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 54. Sweden Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 55. Sweden Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 56. Sweden Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 57. Sweden Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 58. Sweden Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 59. Norway Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 60. Norway Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 61. Norway Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 62. Norway Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 63. Norway Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 64. Asia Pacific Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
Table 65. Asia Pacific Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 66. Asia Pacific Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 67. Aisa Pacific Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 68. Asia Pacific Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 69. Aisa Pacific Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 70. China Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 71. China Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 72. China Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 73. China Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 74. China Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 75. Japan Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 76. Japan Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 77. Japan Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 78. Japan Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 79. Japan Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 80. India Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 81. India Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 82. India Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 83. India Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 84. India Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 85. South Korea Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 86. South Korea Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 87. South Korea Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 88. South Korea Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 89. South Korea Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 90. Australia Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 91. Australia Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 92. Australia Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 93. Australia Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 94. Australia Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 95. Thailand Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 96. Thailand Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 97. Thailand Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 98. Thailand Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 99. Thailand Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 100. Latin America Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
Table 101. Latin America Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 102. Latin America Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 103. Latin America Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 104. Latin America Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 105. Latin America Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 106. Brazil Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 107. Brazil Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 108. Brazil Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 109. Brazil Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 110. Brazil Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 111. Mexico Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 112. Mexico Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 113. Mexico Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 114. Mexico Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 115. Mexico Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 116. Argentina Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 117. Argentina Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 118. Argentina Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 119. Argentina Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 120. Argentina Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 121. MEA Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
Table 122. MEA Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 123. MEA Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 124. MEA Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 125. MEA Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 126. MEA Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 127. South Africa Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 128. South Africa Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 129. South Africa Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 130. South Africa Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 131. South Africa Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 132. Saudi Arabia Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 133. Saudi Arabia Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 134. Saudi Arabia Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 135. Saudi Arabia Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 136. Saudi Arabia Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 137. UAE Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 138. UAE Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 139. UAE Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 140. UAE Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 141. UAE Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
Table 142. Kuwait Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
Table 143. Kuwait Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
Table 144. Kuwait Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
Table 145. Kuwait Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
Table 146. Kuwait Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Migraine Drugs market: market outlook
Fig. 14 Migraine Drugs competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Migraine Drugs market driver impact
Fig. 18 Migraine Drugs market restraint impact
Fig. 19 Migraine Drugs market: Treatment movement analysis
Fig. 20 Migraine Drugs market: Treatment outlook and key takeaways
Fig. 21 Acute market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Preventive estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Migraine Drugs market: Therapeutic Class movement analysis
Fig. 24 Migraine Drugs market: Therapeutic Class outlook and key takeaways
Fig. 25 CGRP monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 CGRP small molecule antagonists market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Acetylcholine inhibitors/ neurotoxins market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Triptans market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Ditans market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Ergot alkaloids market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Migraine Drugs market: Route of Administration movement analysis
Fig. 34 Migraine Drugs market: Route of Administration outlook and key takeaways
Fig. 35 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Migraine Drugs market: Age Group movement analysis
Fig. 39 Migraine Drugs market: Age Group outlook and key takeaways
Fig. 40 Pediatric market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Adult market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Geriatric market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Migraine Drugs market: Availability movement analysis
Fig. 44 Migraine Drugs market: Availability outlook and key takeaways
Fig. 45 Prescription Drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Over-the-Counter (OTC) Drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Global Migraine Drugs market: Regional movement analysis
Fig. 48 Global Migraine Drugs market: Regional outlook and key takeaways
Fig. 49 Global Migraine Drugs market share and leading players
Fig. 50 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 US key country dynamics
Fig. 52 US market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Canada key country dynamics
Fig. 54 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 UK key country dynamics
Fig. 57 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Germany key country dynamics
Fig. 59 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 France key country dynamics
Fig. 61 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Italy key country dynamics
Fig. 63 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Spain key country dynamics
Fig. 65 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Denmark key country dynamics
Fig. 67 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Sweden key country dynamics
Fig. 69 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Norway key country dynamics
Fig. 71 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 72 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 China key country dynamics
Fig. 74 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Japan key country dynamics
Fig. 76 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 India key country dynamics
Fig. 78 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Thailand key country dynamics
Fig. 80 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 South Korea key country dynamics
Fig. 82 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Australia key country dynamics
Fig. 84 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 85 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Brazil key country dynamics
Fig. 87 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Mexico key country dynamics
Fig. 89 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Argentina key country dynamics
Fig. 91 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 South Africa key country dynamics
Fig. 94 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Saudi Arabia key country dynamics
Fig. 96 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 UAE key country dynamics
Fig. 98 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 99 Kuwait key country dynamics
Fig. 100 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 101 Market share of key market players - Migraine Drugs market